BIIB Stock Overview
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BIIB from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
New Alzheimer's Treatments And Market Expansion Will Shape Future Prospects
My Notes
Capture your thoughts, links and company narrative
Biogen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$150.38 |
| 52 Week High | US$238.00 |
| 52 Week Low | US$128.51 |
| Beta | 0.012 |
| 1 Month Change | 3.33% |
| 3 Month Change | -4.69% |
| 1 Year Change | -32.64% |
| 3 Year Change | -23.92% |
| 5 Year Change | -50.73% |
| Change since IPO | 4,777.19% |
Recent News & Updates
We Think Biogen's (NASDAQ:BIIB) Healthy Earnings Might Be Conservative
Feb 19
Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma
Feb 15Recent updates
We Think Biogen's (NASDAQ:BIIB) Healthy Earnings Might Be Conservative
Feb 19Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma
Feb 15Is Biogen (NASDAQ:BIIB) A Risky Investment?
Feb 10Beaten Down Biogen Stock Looks Attractive At Current Levels
Dec 30Market Cool On Biogen Inc.'s (NASDAQ:BIIB) Earnings
Dec 24Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter
Oct 31Does Biogen (NASDAQ:BIIB) Have A Healthy Balance Sheet?
Oct 01What You Can Learn From Biogen Inc.'s (NASDAQ:BIIB) P/E
Sep 04Biogen: Q2 Earnings, Share Price May Have Bottomed Out As CEO Makes Mark
Aug 17Biogen Stock: Cheapish, But With Few Growth Prospects
Jul 11Is Biogen (NASDAQ:BIIB) Using Too Much Debt?
May 23Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade)
Apr 29Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Apr 28The Price Is Right For Biogen Inc. (NASDAQ:BIIB)
Apr 15Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade)
Feb 14Biotech And Pharma Diversification Pays Off
Jan 25Shareholder Returns
| BIIB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.0% | -0.9% | -3.5% |
| 1Y | -32.6% | -6.3% | 11.9% |
Return vs Industry: BIIB underperformed the US Biotechs industry which returned -6.3% over the past year.
Return vs Market: BIIB underperformed the US Market which returned 11.9% over the past year.
Price Volatility
| BIIB volatility | |
|---|---|
| BIIB Average Weekly Movement | 3.7% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: BIIB has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BIIB's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 7,605 | Chris Viehbacher | www.biogen.com |
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies.
Biogen Inc. Fundamentals Summary
| BIIB fundamental statistics | |
|---|---|
| Market cap | US$21.57b |
| Earnings (TTM) | US$1.63b |
| Revenue (TTM) | US$9.68b |
13.5x
P/E Ratio2.3x
P/S RatioIs BIIB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIIB income statement (TTM) | |
|---|---|
| Revenue | US$9.68b |
| Cost of Revenue | US$2.31b |
| Gross Profit | US$7.37b |
| Other Expenses | US$5.73b |
| Earnings | US$1.63b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 11.15 |
| Gross Margin | 76.12% |
| Net Profit Margin | 16.87% |
| Debt/Equity Ratio | 37.7% |
How did BIIB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/07 04:51 |
| End of Day Share Price | 2025/03/07 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biogen Inc. is covered by 65 analysts. 30 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Brian Skorney | Baird |
| Ishan Majumdar | Baptista Research |